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157* Ciproﬂoxacin shows concentration-dependent killing of
Pseudomonas aeruginosa bioﬁlm in vitro
H. Wang1, H. Wu1, Z. Song1, N. Høiby1. 1Rigshospitalet, University Hospital of
Copenhagen, Department of Clinical Microbiology, Copenhagen, Denmark
Background: Bioﬁlm mode of growth is likely a main reason why the Pseudomonas
aeruginosa (PA) lung infection in cystic ﬁbrosis (CF) is rarely eradicated. The
purpose of this study was to evaluate the killing activity of Ciproﬂoxacin on non-
mucoid and mucoid PA bioﬁlm on different time points in vitro.
Methods: Killing curves of Ciproﬂoxacin on bioﬁlms of non-mucoid PAO1,
PAO579, and mucoid PDO300 were made on days 1, 3 and 7. The microtiter
plate method was used to test minimal inhibitory concentration (MIC) and minimal
bactericidal concentration (MBC) for planktonic bacteria, and the minimal bioﬁlm
inhibition concentration (MBIC) and minimal bioﬁlm eradication concentration
(MBEC) were done on days 1, 3 and 7.
Results: Ciproﬂoxacin showed concentration-dependent killing activity for bioﬁlms
of non-mucoid PAO1, PAO579, and mucoid PDO300 on days 1, 3 and 7. The MIC
and MBC for planktonic PAO1, PAO579, PDO300 were 0.125, 0.125, 0.25 mg/ml
and 0.25, 0.5, 2mg/ml respectively. MBIC of PAO1, PAO579, PDO300 was 1, 1,
4mg/ml (day 1 bioﬁlm); 4, 4, 8mg/ml (day 3 bioﬁlm) and 4, 8, 16mg/ml (day 7
bioﬁlm) respectively. MBEC of PAO1, PAO579, PDO300 was 16, 16, 32 mg/ml
(day 1 bioﬁlm); 64, 64, 128 mg/ml (day 3 bioﬁlm) and 32, 64, 128 mg/ml (day 7
bioﬁlm) respectively.
Conclusion: The killing activity of Ciproﬂoxacin was found to be concentration-
dependent on bioﬁlm growing PA of non-mucoid PAO1, PAO579, and mucoid
PDO300. MBIC and MBEC of Ciproﬂoxacin were much higher than the MIC and
MBC of the planktonic PA. MBIC and MBEC on day 3 and day 7 were higher
than the value on day 1. The results suggest the importance of early treatment on
bioﬁlm infection of PA in CF patients.
158 Increasing antibiotic resistance with the Liverpool Epidemic
Pseudomonas aeruginosa Strain (LES) − a 5-year study
A. Ashish1, H. Sedmakov1, M.J. Ledson1, M.J. Walshaw1. 1Liverpool Heart and
Chest Hospital, Liverpool, United Kingdom
The use of powerful antibiotics therapy for infective exacerbations with Pseu-
domonas aeruginosa (Psa) in CF can induce antibiotic resistance over time, thereby
complicating their treatment. Although infection with transmissible Psa strains has
been shown to require more treatment and confer a worse prognosis, there have been
no studies comparing the antibiotic resistance patterns of LES (the commonest UK
transmissible strain, widespread in UK CF clinics) to unique Psa strains over time.
To investigate this further, we matched (for age, years since CF diagnosis, FEV1,
BMI, and Psa antibiograms to ciproﬂoxacin, tobramycin, ceftazidime, meropenem,
tazocin and colomycin) 22 adult CF patients chronically infected with LES to
22 infected with unique strains and looked for changes in their Psa antibiograms
over a 5 year period. Fisher’s exact test was used to analyse statistical signiﬁcance.
LES became developed increasingly resistant antibiograms over time, compared to
the unique strains (see table).
Antibiotic resistance in LES vs unique strains
Year 1 Psa Year 5 Psa
Unique LES p value Unique LES p value
Sensitive 20 (90%) 17 (77%) NS 19 (85%) 4 (18%) <0.001
Multiresistant 2 (10%) 3 (13%) NS 1 (5%) 14 (64%) <0.001
Panresistant 0 (0%) 2 (10%) NS 2 (10%) 4 (18%) NS
For the ﬁrst time, this study has shown that patients infected with the common
transmissible UK Psa strain (LES) are becoming increasingly difﬁcult to treat.
This re-enforces the need to adopt effective cross infection control policies in the
CF community to prevent spread of these damaging organisms.
159* Eradication of methicillin-resistant Staphylococcus
aureus (MRSA) in adult patients attending a regional
cystic ﬁbrosis centre
C. Etherington1, S. Conway1, D. Peckham1, M. Denton2, M. Rasheed1. 1St James’s
University Hospital, Leeds, United Kingdom; 2Microbiology Department, Leeds
Teaching Hospitals Trust, Leeds, United Kingdom
Introduction: This study evaluated the success rate of an eradication protocol for
new isolates of MRSA in adults with CF attending a large Regional Adult CF Unit.
Methods: Case notes of all new MRSA isolates acquisitions between 1st January
2006 and 31st December 2009 were reviewed retrospectively. Patients with a new
isolates of MRSA were offered eradication treatment [Unit protocol 2% nasal
mupirocin, topical chlorhexidine 4% and nebulised vancomycin (250mg twice
daily) for ﬁve days, followed by three months of Rifampicin 600mg daily and
Sodium fusidate 500mg twice daily]. From July 2007 these were prescribed for
only one month.
Results: New isolates of MRSA were reported in 22 patients (median age 26 yrs,
FEV1 52% and BMI 22) with an incidence of 2% in 2006, 0.6% in 2007,
0.9% in 2008 and 2.8% in 2009. 21 patients received eradication therapy, time
to treatment 10 days. Nasal/skin carriage was performed in 17 patients (81%),
2/17 were positive. Screening of family members was performed in 12 pa-
tients (57%), 1/12 were positive. To date 17 patients remain MRSA-free with a
median follow-up of 13.5 months; success rate 81%. Four patients have regrown
MRSA; median time to recurrence 15.3 (1.8–30.1) months; 2/4 had positive nasal
carriage and/or positive family screening. Only one patient (4.8%) is chronically
colonised. Increased success rate following change from three months to one month
of oral antibiotic treatment (63% vs. 100%, p< 0.001).
Conclusions: Eradication of MRSA in patients with CF is feasible and has a high
success rate. Determining carrier status and screening of family members is essential
to identify those at risk of early recurrence.
160* Macrolide resistance of Staphylococcus aureus isolates
obtained from respiratory tract samples of people with
cystic ﬁbrosis
I. Whalley1, J. Ross2, C. Etherington3, S.P. Conway4, M. Denton1. 1Leeds
General Inﬁrmary, Microbiology, Leeds, United Kingdom; 2University of Bradford,
Microbiology, Bradford, United Kingdom; 3St James’s University Hospital, Adult
Cystic Fibrosis Unit, Leeds, United Kingdom; 4St James’s University Hospital,
Paediatric Cystic Fibrosis Unit, Leeds, United Kingdom
Introduction: The routine use of azithromycin in CF has been associated with
increased macrolide resistance in Staphylococcus aureus. We have studied the
phenotypic and molecular characteristics of this resistance in the Leeds CF clinics.
Methods: Single isolates of S. aureus were collected from respiratory samples of 84
people with CF between August 2007 and July 2008. MICs to erythromycin (ERY),
clindamycin (CLI) and azithromycin (AZI) were determined by Etest. Resistance
phenotypes were determined using ERY-CLI disc approximation. Presence of
macrolide resistance genes ermA, ermB, ermC and msrA was determined by PCR.
Clonal relationships between strains were determined using PFGE.
Results: Macrolide resistance was detected in 69/84 (82%) of isolates. Ten (12%)
isolates were MRSA. AZI MICs ranged from 0.06 to >256mg/l. Five different re-
sistance phenotypes were seen using ERY-CLI disc approximation. In the macrolide-
resistant isolates the genes most frequently detected were ermC (28% isolates) and
ermA (26% isolates). PFGE showed that most isolates were clonally unrelated,
except for a small cluster of a UK epidemic MRSA strain.
Conclusions: The recent rise in macrolide resistance in S. aureus isolated from
people attending the Leeds CF clinics has not been caused by the dissemination of
a resistant clone. Rather, the increase appears to have occurred through the multiple,
independent emergence of a number of different resistance mechanisms in unrelated
strains.
